1. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
- Author
-
Alexandra Landras, Coralie Reger de Moura, Bruno O. Villoutreix, Maxime Battistella, Aurélie Sadoux, Nicolas Dumaz, Suzanne Menashi, Juan Fernández-Recio, Céleste Lebbé, Samia Mourah, Ligue Nationale contre le Cancer (France), Institut National de la Santé et de la Recherche Médicale (France), Société Française de Dermatologie, Ministerio de Ciencia, Innovación y Universidades (España), and Agencia Estatal de Investigación (España)
- Subjects
Proto-Oncogene Proteins B-raf ,Cancer Research ,Cell Line, Tumor ,Mutation ,Genetics ,Basigin ,Humans ,Membrane Proteins ,Molecular Biology ,Melanoma ,Protein Kinase Inhibitors ,Vascular Endothelial Growth Factor Receptor-2 ,GTP Phosphohydrolases - Abstract
More than 70% of human NRAS melanomas are resistant to MEK inhibitors highlighting the crucial need for efficient therapeutic strategies for these tumors. CD147, a membrane receptor, is overexpressed in most cancers including melanoma and is associated with poor prognosis. We show here that CD147i, a specific inhibitor of CD147/VEGFR-2 interaction represents a potential therapeutic strategy for NRAS melanoma cells. It significantly inhibited the malignant properties of NRAS melanomas ex vivo and in vivo. Importantly, NRAS patient’s-derived xenografts, which were resistant to MEKi, became sensitive when combined with CD147i leading to decreased proliferation ex vivo and tumor regression in vivo. Mechanistic studies revealed that CD147i effects were mediated through STAT3 pathway. These data bring a proof of concept on the impact of the inhibition of CD147/VEGFR-2 interaction on melanoma progression and represents a new therapeutic opportunity for NRAS melanoma when combined with MEKi., This work was supported by La Ligue Nationale contre le Cancer, the Institut National de la Santé et de la Recherche Médicale (INSERM) and La Société Française de Dermatologie. AL was supported by a PhD funding from La Ligue Nationale contre le Cancer and the Spanish Ministry of Science and Innovation (PID2019-110167RB-I00). We thank technological platform of the Institut Recherche Saint-Louis (IRSL) for confocal microscopy analyses and Dr Benoit Souquet for technical support.
- Published
- 2022